References
- Lemas HM. Reduction of 5-fluorouracil toxicity in man with retention of anticancer effects by prolonged intravenous ad-ministration in 5% dextrose. Cancer Chemother 1960; 8: 97–101.
- Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE. Non-linear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 1980; 28: 235–46.
- Liver Infusion Meta-analysis Group. Portal vein chemother-apy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997; 8: 497–505.
- Vokes EE, Schilksky RL, Choi KE. A randomised study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer 1989; 63: 30–6.
- Jones AL, Smith IE, O'Brien ME, et al. Phase II study of continuous infusion fluorouracil with epirubicin and cisplat-inum in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol 1994; 12: 1259–65.
- Hickman RO, Buckner CD, Clift RA. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynaecol Obstet 1979; 148: 871–5.
- Raad I, Davis S, Becker M, et al. Low infection rate and long durability of non-tunnelled silastic catheters. Arch Int Med 1993; 153: 1791–6.
- Adam A. Insertion of long term venous catheters: time for a new look. Br Med J 1995; 311: 341–2.
- Cockburn JF, Eynon CA, Virji N. Insertion of Hickman central venous catheters by using angiographic techniques in patients with haematologic disorders. Am J Radiol 1992; 159: 121–4.
- Levine M, Hirsh J, Gent M. Double-blind randomised trial of very low dose warfarin for prevention of thrombo-embolism in Stage IV breast cancer. Lancet 1994; 343: 886–9.
- Bern MM, Lokich JJ, Wallach SR. Very low doses of war-farin can prevent thrombosis in central venous catheters. A randomised prospective trial. Ann Int Med 1990; 112: 423–8.
- Evans TRJ, Lofts FJ, Mansi JL, Glees JP, Dalgeish AG, Knight MJ. A phase two study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable breast cancer. Br J Cancer 1996; 73: 1260–4.
- Lokich JJ, Bothe A, Benotti PN. Complications and manage-ment of implanted venous access catheters. J Clin Oncol 1985; 3: 710–7.
- Rigg A, Hughes P, Lopez A. Right phrenic nerve palsy as a complication of indwelling central venous catheters. Thorax 1997; 52: 831–3.
- Manheimer F, Aranda CD, Smith RL. Necrotising pneu-monitis caused by 5-fluorouracil infusion. Cancer 1992; 70: 554–6.
- Page AC, Evans RA, Kaczmarski R. The insertion of chronic indwelling central venous catheters (Hickman lines) in inter-ventional radiology suites. Clin Radiol 41 1990; 41: 105–9.
- Mueller BU, Skelton J, Callander DPE, et al. A prospective randomised trial comparing the infectious and noninfectious complications of an externalised catheter versus a subcuta-neously implanted device in cancer patients. J Clin Oncol 1992; 12: 1943–8.
- Harrington KJ, Kelly SA, Pandha JE, Jackson JE, Hollyer JS, McKenzie CG. An audit of Hickman catheters use in patients with solid tumours. Clin Oncol 1994; 6: 288–93.
- Howell PB, Walters PE, Donowitz GR, Farr BM. Risk factors for infection of adult patients with cancer who have tunnelled venous catheters. Cancer 1994; 6: 1367–75.
- Bisset D, Kaye SB, Baxter G, Moss J. Successful thrombolysis of SVC thrombosis associated with Hickman lines and contin-uous infusion chemotherapy. Clin Oncol 1996; 8: 247–9.
- Nightingale CE, Norman A, Cunningham D, Young J, Webb A, Filshie J. A prospective analysis of 949 long term central venous access catheters for ambulatory chemotherapy in pa-tients with gastrointestinal malignancy. Eur J Cancer 1997; 3: 398–403.